Evaluation of Constipation in Patients with Parkinson’s Disease and its Correction
Objective: To evaluate the possible causes of constipation, and to find clear methods to correct the disorder. Background: Constipation is a common problem in Parkinson's…Intestinal nerve damage and gut dysfunction in mouse models of Parkinson’s Disease
Objective: This work aims to investigate gut dysfunction and enteric neuropathy in several mouse models of PD to provide insight into enteric nervous system (ENS)…Functional Bowel Symptoms in Parkinson´s Disease
Objective: We assessed the prevalence of functional bowel disorders in patients with Parkinson´s disease (PD) using Rome III criteria. Background: A significant fraction of PD…MIBG myocardial scintigraphy identifies premotor PD/DLB during a negative DAT scan period
Objective: It is unknown which marker is useful to identify the premotor phase PD/DLB. We recently reported four patients who, during a negative DAT scan…Characteristics of lower gastrointestinal tract dysfunction in patients with Parkinson disease
Objective: To evaluate the characteristics of lower gastrointestinal tract dysfunction in patients with Parkinson disease (PD). Background: Lower gastrointestinal tract dysfunction is common in patients…Characterization of the gastrointestinal dysfunction in the 6-hydroxydopamine rat model of Parkinson’s disease
Objective: To characterize the gastrointestinal (GI) phenotype in the 6-hydroxydopamine (6OHDA) rat model of Parkinson’s disease (PD). Background: GI dysfunction, such as prolonged GI transit…A Prospective Study of the Effects of Deep Brain Stimulation on Constipation and Olfaction in Parkinson Disease
Objective: To investigate the effects of subthalamic nucleus deep brain stimulation (STN-DBS) on constipation and olfaction in patients with Parkinson disease (PD). Background: STN-DBS is…Gastrointestinal microbiome in Parkinson’s disease in a Bavarian cohort
Objective: Our goal was to evaluate, whether gut microbiota are altered in a Southern German PD cohort. In addition, we assessed changes in the microbiome…Path to Prevention (P2P) – Developing a Prodromal PD Progression Biomarker Program
Objective: The overall objective of the Path to Prevention (P2P) initiative is to identify clinical, imaging, and biologic markers of progression during the prodromal phase…The Dutch Parkinson and Microbiome Study (DUPARM): Gut Microbiome Composition of Treatment-Naïve De Novo Parkinson’s Disease Patients
Objective: To establish the gut microbiome composition of de novo Parkinson’s disease (PD) patients with no history of dopaminergic medication use. Background: PD is often…